Sign in to continue:

Saturday, May 2nd, 2026

Intel Corporation Announces Senior Notes Offering to Repay Apollo Minority Interest in Irish Wafer Fabrication Plant





Intel Corporation Announces Multi-Series Senior Notes Offering – Investor Update

Intel Corporation Announces \$7 Billion Senior Notes Offering to Repurchase Minority Interest in Irish Wafer Plant

Key Points for Investors

  • Intel Corporation has completed a significant offering of senior notes totaling \$7 billion across five series with maturities from 2031 to 2066.
  • The proceeds are earmarked to repay a bridge loan related to the repurchase from Apollo-managed funds and affiliates of their 49% minority ownership interest in Intel’s majority-owned and consolidated joint investment entity tied to the output of its wafer fabrication plant in Ireland.
  • This move effectively increases Intel’s direct ownership and control of critical manufacturing assets, which could have major implications for the company’s operational flexibility and financial profile.
  • The offering was executed under a non-delayed SEC registration, reflecting robust market interest and efficient execution.

Details of the Senior Notes Offering

  • Series and Principal Amounts:

    • 4.650% Notes due 2031: \$1,000,000,000
    • 5.000% Notes due 2033: \$1,000,000,000
    • 5.300% Notes due 2036: \$2,000,000,000
    • 6.125% Notes due 2056: \$1,750,000,000 (corrected from previous filings)
    • 6.200% Notes due 2066: \$1,250,000,000
  • Price to Public: The notes were priced at 99.935% of principal amount, plus accrued interest from April 30, 2026, if any.
  • Settlement and Trading: Expected settlement date is April 30, 2026 (T+3). Trading symbols and exchange information are as follows:

    • Trading Symbol: INTC
    • Exchange: Nasdaq Global Select Market
  • Benchmark Treasury: UST 4.250% due March 31, 2033, priced at 100-22+ / Yield: 4.132%
  • Par Call: For the 2066 notes, par call available on or after November 15, 2065.

Underwriting and Syndicate

The offering was underwritten by a syndicate led by Citigroup Global Markets Inc., J.P. Morgan Securities LLC, Barclays Capital Inc., BofA Securities, Inc., and Deutsche Bank Securities Inc., with participation from a broad array of global investment banks, including Goldman Sachs, Morgan Stanley, BNP Paribas, Mizuho Securities, RBC Capital Markets, TD Securities, Wells Fargo, Commerz Markets, Credit Agricole, NatWest Markets, Standard Chartered, Academy Securities, Loop Capital Markets, and Siebert Williams Shank & Co.

Strategic Implications for Shareholders

  • Repurchase of Minority Interest: The primary use of proceeds is to repay the bridge loan used to repurchase the 49% minority stake held by Apollo-managed funds in the Irish wafer fabrication entity. This transaction consolidates Intel’s control of vital manufacturing capacity, potentially improving margins and operational security.
  • Impact on Capital Structure: Issuing \$7 billion in long-term debt increases leverage but locks in fixed rates at a time when borrowing costs, though elevated, may be favorable compared to future market conditions. The company’s ability to attract such a large syndicate and demand indicates strong market confidence in Intel’s credit and business outlook.
  • Potential Share Price Sensitivity: The consolidation of manufacturing assets and the reduction of outside interests in a key joint venture could lead to improved earnings visibility and strategic flexibility. However, the increased leverage and long maturities mean shareholders should monitor Intel’s debt service and future capital needs.
  • No Emerging Growth Company Status: Intel is not an “emerging growth company” and has not elected to use extended transition periods for new accounting standards—indicating full compliance with current financial reporting requirements.
  • Financial Reporting and Risk: The financial statements incorporated by reference present Intel’s consolidated financial position and are prepared in accordance with GAAP. There have been no material adverse changes in capital stock, long-term debt, or business as of the dates referenced, except for those disclosed as part of this offering.
  • Regulatory and Legal: The offering documents include robust indemnification and contribution provisions between Intel and the underwriters, reflecting standard protections for securities offerings of this size.

Potential Risks and Considerations

  • The addition of \$7 billion in debt affects Intel’s leverage ratios. While long maturities and fixed rates mitigate some risk, investors must monitor future cash flows, interest coverage, and the company’s ability to service debt.
  • With increased ownership in the Irish wafer plant, Intel assumes greater direct exposure to operational risks and capital expenditure requirements.
  • Any unforeseen adverse developments in the semiconductor market or manufacturing disruptions could affect Intel’s ability to fulfill debt obligations.
  • Changes in credit ratings could impact the value of these notes and Intel’s future borrowing costs.

Conclusion

Intel’s senior notes offering is a transformational move, consolidating ownership of a key manufacturing asset and locking in long-term financing. Investors should note the strategic benefits from increased control, but also the higher debt load and associated risks. The market’s confidence in Intel’s credit is evident from the breadth of the underwriting syndicate and the successful pricing and execution of the deal.


Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell Intel Corporation securities. Investors should consult their financial advisors and review the full SEC filings before making any investment decisions. The information herein is based on public filings and is subject to change without notice.




View INTEL CORP Historical chart here



Evercore Inc. 2025 Annual Report: Business Overview, Financials, Growth Strategies, and Regulatory Insights

Evercore Inc. 2025 Annual Report: Key Highlights and Shareho...

MetaVia Inc 2025 Annual Report: Clinical Progress, Risk Factors, and Cardiometabolic Drug Pipeline Overview

MetaVia Inc. Annual Report 2025 – Key Highlights and Investo...

   Ad

Join Our Investing Seminar

Limited seats available — Reserve your spot today